This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Locher, H. H. Articles by Then, R. L. Search for Related Content PubMed PubMed Citation Articles by Locher, H. H. Articles by Then, R. L.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, 06 1996, 1376-1381, Vol 40, No. 6
Copyright © 1996 by the American Society for Microbiology. All rights reserved.

Antibacterial activities of epiroprim, a new dihydrofolate reductase inhibitor, alone and in combination with dapsone

HH Locher, H Schlunegger, PG Hartman, P Angehrn and RL Then
Pharma Division, F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Epiroprim (EPM; Ro 11-8958) is a new selective inhibitor of microbial dihydrofolate reductase. EPM displayed excellent activity against staphylococci, enterococci, pneumococci, and streptococci which was considerably better than that of trimethoprim (TMP). EPM was also active against TMP-resistant strains, although the MICs were still relatively high. Its combination with dapsone (DDS) was synergistic and showed as in vitro activity superior to that of the TMP combination with sulfamethoxazole (SMZ). The EPM-DDS (ratio, 1:19) combination inhibited more than 90% of all important gram-positive pathogens at a concentration of 2 + 38 micrograms/ml. Only a few highly TMP-resistant staphylococci and enterococci were not inhibited. EPM was also more active than TMP against Moraxella catarrhalis, Neisseria meningitidis, and Bacteroides spp., but it was less active than TMP against all other gram-negative bacteria tested. Atypical mycobacteria were poorly susceptible to EPM, but the combination with DDS was synergistic and active at concentrations most probably achievable in biological fluids (MICs from 0.25 +/- 4.75 to 4 + 76 micrograms/ml). EPM and the EPM-DDS combination were also highly active against experimental staphylococcal infections in a mouse septicemia model. The combination EPM-DDS has previously been shown to exhibit activity in Pneumocystis carinii and Toxoplasma models and, as shown in the present study, also shows good activity against a broad range of bacteria including many strains resistant to TMP and TMP-SMZ.

This article has been cited by other articles:

• Laue, H., Weiss, L., Bernardi, A., Hawser, S., Lociuro, S., Islam, K. (2007). In vitro activity of the novel diaminopyrimidine, iclaprim, in combination with folate inhibitors and other antimicrobials with different mechanisms of action. J Antimicrob Chemother 60: 1391-1394 [Abstract] [Full Text]  
• Gerum, A'L. B., Ulmer, J. E., Jacobus, D. P., Jensen, N. P., Sherman, D. R., Sibley, C. H. (2002). Novel Saccharomyces cerevisiae Screen Identifies WR99210 Analogues That Inhibit Mycobacterium tuberculosis Dihydrofolate Reductase. Antimicrob. Agents Chemother. 46: 3362-3369 [Abstract] [Full Text]  
• Suling, W. J., Seitz, L. E., Pathak, V., Westbrook, L., Barrow, E. W., Zywno-van-Ginkel, S., Reynolds, R. C., Piper, J. R., Barrow, W. W. (2000). Antimycobacterial Activities of 2,4-Diamino-5-Deazapteridine Derivatives and Effects on Mycobacterial Dihydrofolate Reductase. Antimicrob. Agents Chemother. 44: 2784-2793 [Abstract] [Full Text]  
• Coque, T. M., Singh, K. V., Weinstock, G. M., Murray, B. E. (1999). Characterization of Dihydrofolate Reductase Genes from Trimethoprim-Susceptible and Trimethoprim-Resistant Strains of Enterococcus faecalis. Antimicrob. Agents Chemother. 43: 141-147 [Abstract] [Full Text]